Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IMC002
i
Other names:
IMC002, Claudin 18.2 CAR-T
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Immunofoco
Drug class:
CLDN18.2-targeted CAR-T immunotherapy
Related drugs:
‹
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LB1908 (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LB1908 (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
›
Associations
News
Trials
Filter by
Latest
1year
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
1 year ago
Enrollment open • Metastases
|
CLDN18 (Claudin 18) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CLDN18.2 positive
|
IMC002
over1year
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
over 1 year ago
New P1 trial • Metastases
|
CLDN18 (Claudin 18) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CLDN18.2 positive
|
IMC002
2years
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression (clinicaltrials.gov)
P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2034 --> Dec 2024
2 years ago
Enrollment open • Trial completion date • CAR T-Cell Therapy • Metastases
|
CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
|
IMC002
over2years
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
over 2 years ago
New P1 trial • CAR T-Cell Therapy
|
CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
|
IMC002
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login